AUSTIN, Texas, June 8, 2021 /PRNewswire/ — MorphImmune, Inc., a Research Bridge Partners portfolio company that is advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system, announced the appointment of Ronald Martell as the…